Atricure Inc Revenue Growth Rates (ATRC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Atricure Inc   (NASDAQ: ATRC)
 

ATRC's Revenue Growth by Quarter and Year

Atricure Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ATRC/growth
https://api.csimarket.com/api/v1/companies/ATRC/fundamentals
https://api.csimarket.com/api/v1/companies/ATRC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ATRC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 154.45
2nd Quarter June 153.60
1st Quarter March 140.31
FY 448.36

ATRCs Annual Revenue
Atricure Inc 's Revenue in the fiscal year 2025 $ 533.78 millions
Atricure Inc 's Revenue in the fiscal year 2024 $ 464.52 millions
Atricure Inc 's Revenue in the fiscal year 2023 $ 398.37 millions
Atricure Inc 's Revenue in the fiscal year 2022 $ 330.38 millions
Atricure Inc 's Revenue in the fiscal year 2021 $ 274.33 millions




ATRC Revenue third quarter 2026 Y/Y Growth Comment
Atricure Inc reported Revenue increase of 15.84% year on year in the third quarter 2026, to $ 154.45 millions, this is lower than Atricure Inc 's recent average Revenue increase of 17.44%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 110 other companies have achieved higher Revenue growth. While Atricure Inc ' s Revenue growth of 15.84% ranks overall at the positon no. 2043 in the third quarter 2026.


ATRC Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.84 %
2nd Quarter June 13.37 %
1st Quarter March 14.42 %
FY   -

Financial Statements
Atricure Inc 's third quarter 2026 Revenue $ 154.45 millions ATRC's Income Statement
Atricure Inc 's third quarter 2025 Revenue $ 133.33 millions Quarterly ATRC's Income Statement


ATRC Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.55 %
2nd Quarter June 9.47 %
1st Quarter March -0.14 %
FY (Year on Year)   -


Back to ATRC Growth rate Comparisons >> Back to ATRC Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #111
Healthcare Sector #306
Overall #2043

Revenue Y/Y Growth Statistics
High Average Low
37.48 % 17.44 % -10.52 %
(Sep 30 2014)   (Dec 31 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #111
Healthcare Sector #306
Overall #2043
Revenue Y/Y Growth Statistics
High Average Low
37.48 % 17.44 % -10.52 %
(Sep 30 2014)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Atricure Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
34.13 % 4.11 % -23.3 %
(Sep 30 2020)  


ATRC's III. Quarter Q/Q Revenue Comment
Atricure Inc achieved in the III. Quarter 2026 below company average Revenue growth of 0.55% quarter on quarter, to $ 154.45 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -1.59% growth in the III. Quarter a year ago

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Atricure Inc 's Revenue growth quarter on quarter, overall rank is 826.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #126
Overall #826
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #126
Overall #826
Revenue Q/Q Growth Statistics
High Average Low
34.13 % 4.11 % -23.3 %
(Sep 30 2020)  


ATRC's III. Quarter Q/Q Revenue Comment
Atricure Inc achieved in the III. Quarter 2026 below company average Revenue growth of 0.55% quarter on quarter, to $ 154.45 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -1.59% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Atricure Inc 's Revenue growth quarter on quarter, overall rank is 826.


Atricure Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 567.75
Y / Y Revenue Growth (TTM) 13.96 %
Year on Year Revenue Growth Overall Ranking # 955
Seqeuential Revenue Change (TTM) 3.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 2046


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Atricure Inc 's cumulative twelve months Revenue were $ 568 millions, company would post below average annual Revenue growth of 3.3% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Atricure Inc 's Revenue growth from the 153.6% growth in Mar 31 2026.

In the Healthcare sector 196 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 574 to 955.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 111
Healthcare Sector # 197
Overall # 955

Revenue TTM Y/Y Growth Statistics
High Average Low
37.48 %
 17.44 %
-10.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 111
Sector # 306
S&P 500 # 2046
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Atricure Inc 's cumulative twelve months Revenue were $ 568 millions, company would post below average annual Revenue growth of -10.52% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Atricure Inc 's Revenue growth from the 153.6% growth in Mar 31 2026.

In the Healthcare sector 196 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 574 to 955.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 111
Healthcare Sector # 197
Overall # 955

Revenue TTM Y/Y Growth Statistics
High Average Low
37.48 %
17.44 %
-10.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 111
Sector # 306
S&P 500 # 2046




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ATRC's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions


About Atricure Inc Revenue Growth Rates (ATRC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Atricure Inc (CIK 1323885).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001323885-26-000040
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Atricure Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.